Clinical trial · Observational
Lymph Fluid and Blood Collection for Identification of Novel Biomarkers
The Comparison of Lymph Fluid and Blood From Metastatic and Non-metastatic Invasive Breast Cancer Patients for Identification of Novel Biomarkers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Halted prematurely due to lack of funding.
Summary
Brief summary (as posted)
The objective of this study is to identify and validate metastasis protein markers in lymph collected from women with metastatic breast cancer. We will examine peripheral blood for the presence of these identified markers in order to develop a user friendly clinical test to detect metastasis and to evaluate response to therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma of the Breast | Breast Adenocarcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Identification and Validation of Metastasis Protein Markers
- timeFrame
- Every 6 mo. for 5 years
- description
- Lymph fluid collected at surgery; blood collected at surgery and then every 6 months for 5 years.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Women, age greater than or equal to 18, with histologically and/or cytologically confirmed diagnosis of adenocarcinoma of the breast with metastatic (node positive) and/or non-metastatic (node negative) breast cancer. * No prior chemotherapy treatment. * Women, age greater than or equal to 18, with carcinoma in situ that opted for mastectomy. * Able to provide informed consent and HIPAA authorization. Exclusion Criteria: * Hormone therapy in the past six months. Birth control pill use is allowed. * History of radiation therapy to the chest. * Previous or current use of aromatase inhibitor (AI) or Selective Estrogen Receptor Modulator (SERM) medication. * History of chemotherapy for breast or other cancers. * Pregnant or breast-feeding.
References
Publications (0)
Data not yet available